The Patent Finder

Genticel

Also on record
Records under this name other than the patents Genticel holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 7 of 7 · Back to Genticel

PatentTitleStatus Expires Confidence
US 9,982,024CyaA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
Lapsed on the fee record
Ended May 29, 2026 · From the USPTO record
Lapsed on the fee recordEnded May 29, 2026From the USPTO record
US 8,628,779Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof
Lapsed on the fee record
Ended Jan 14, 2026 · High confidence
Lapsed on the fee recordEnded Jan 14, 2026High confidence
US 9,827,302HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
Lapsed on the fee record
Ended Nov 28, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 28, 2025From the USPTO record
US 8,637,039Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof
Term ended
Term ended Sep 23, 2025 · From the USPTO record
Term endedTerm ended Sep 23, 2025From the USPTO record
US 9,387,243Recombinant Protein Carrying Human Papillomavirus Epitopes Inserted in an Adenylate Cyclase Protein or Fragment Thereof Therapeutic Uses Thereof
Lapsed on the fee record
Ended Jul 12, 2024 · Low confidence
Lapsed on the fee recordEnded Jul 12, 2024Low confidence
US 9,902,947CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
Lapsed on the fee record
Ended Feb 27, 2022 · From the USPTO record
Lapsed on the fee recordEnded Feb 27, 2022From the USPTO record
US 9,486,524Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
Lapsed on the fee record
Ended Nov 8, 2020 · From the USPTO record
Lapsed on the fee recordEnded Nov 8, 2020From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited